<div id="readability-page-1"><p>Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) were down 3.6% during mid-day trading on Monday following insider selling activity. The stock traded as low as $79.36 and last traded at $79.8450. Approximately 86,438 shares traded hands during trading, a decline of 77% from the average daily volume of 377,608 shares. The stock had previously closed at $82.85.</p><div><p><span></span><span>Get <strong>ANI Pharmaceuticals</strong> alerts:</span></p></div><p>Specifically,  SVP Krista Davis sold 1,622 shares of the business's stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80. Following the completion of the transaction, the senior vice president directly owned 58,564 shares in the company, valued at $4,825,673.60. The trade was a 2.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. </p><h2>Analyst Ratings Changes</h2><p>ANIP has been the topic of a number of research analyst reports. Guggenheim raised their target price on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a &#34;buy&#34; rating in a report on Monday, November 10th. HC Wainwright upped their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, September 17th. Barclays initiated coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an &#34;overweight&#34; rating and a $100.00 price objective on the stock. Truist Financial lifted their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a &#34;hold&#34; rating in a research report on Thursday, October 9th. Finally, Weiss Ratings cut shares of ANI Pharmaceuticals from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a report on Monday, December 15th. One research analyst  has rated the stock with a Strong Buy rating, six have assigned  a Buy rating and two have assigned  a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals  has an average rating of &#34;Moderate Buy&#34; and an average price target of $102.14.</p><p><b>Check Out Our Latest Analysis on ANI Pharmaceuticals</b></p><h2>ANI Pharmaceuticals Stock Down 3.6%</h2><p>The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of 49.04 and a beta of 0.48. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The stock has a 50 day moving average price of $86.70 and a 200 day moving average price of $81.62. </p><p>ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. During the same quarter last year, the business earned $1.34 EPS. The firm's quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS.  As a group, analysts forecast that  ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year. </p><h2>Institutional Trading of ANI Pharmaceuticals</h2><p>Several institutional investors have recently modified their holdings of the business. Intech Investment Management LLC lifted its holdings in shares of  ANI Pharmaceuticals by 134.7% in the 2nd quarter. Intech Investment Management LLC now owns 26,917 shares of the specialty pharmaceutical company's stock worth $1,756,000 after purchasing an additional 15,447 shares in the last quarter.  Envestnet Asset Management Inc. increased its stake in  ANI Pharmaceuticals by 59.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,326 shares of the specialty pharmaceutical company's stock valued at $674,000 after purchasing an additional 3,869 shares in the last quarter.  Squarepoint Ops LLC acquired a new position in  ANI Pharmaceuticals during the second quarter worth $2,137,000.  Dynamic Technology Lab Private Ltd acquired a new position in  ANI Pharmaceuticals during the second quarter worth $209,000.  Finally, Sio Capital Management LLC lifted its stake in shares of  ANI Pharmaceuticals by 29.4% in the second quarter. Sio Capital Management LLC now owns 112,923 shares of the specialty pharmaceutical company's stock valued at $7,368,000 after buying an additional 25,625 shares in the last quarter. Institutional investors own  76.05% of the company's stock. </p><h2>ANI Pharmaceuticals Company Profile</h2> (Get Free Report)<p>ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.  </p><p>ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than ANI Pharmaceuticals</li><li>The Fed Pivot Signal Smart Money’s Been Waiting For</li><li>This AI–Quantum Company Expects to Hit $274M in Revenue for 2025</li><li>Wall Street Stock picker Names #1 Stock of 2026</li><li>Do not delete, read immediately</li><li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p><p>While ANI Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ANIP

<p>ANI Pharmaceuticals' stock (NASDAQ:ANIP) fell 3.6% following insider selling by SVP Krista Davis, who sold 1,622 shares. The stock traded at a low of $79.36, with a significant drop in trading volume. Despite the decline, analysts maintain a "Moderate Buy" rating with an average price target of $102.14. The company reported strong quarterly earnings, beating estimates, and has a market cap of $1.79 billion.</p>

ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 3.6% on Insider Selling